Zeng Y, Zhang R, Wu J,et al. Organic anion transporter 1 (OAT1) involved in renal cell transport of aristolochic acid I[J]. Human Experi Toxicol,2012, 31(8): 759.
[2]
Jiang Z, Bao Q, Sun L,et al. Possible role of mtDNA depletion and respiratory chain defects in aristolochic acid I-induced acute nephrotoxicity[J]. Toxicol Applied Pharmacol,2013, 266(2): 198.
[3]
Zhu S, Wang Y, Jin J,et al. Endoplasmic reticulum stress mediates aristolochic acid I-induced apoptosis in human renal proximal tubular epithelial cells[J]. Toxicol In Vitro, 2012, 26(5): 663.
[4]
Li Y C, Tsai S H, Chen S M,et al. Aristolochic acid-induced accumulation of methylglyoxal and nepsilon-(carboxymethyl)lysine: an important and novel pathway in the pathogenic mechanism for aristolochic acid nephropathy[J]. Biochem Biophys Res Communic,2012, 423(4): 832.
Wang Y, Fu W, Wang H,et al. Renal microvascular injury in chronic aristolochic acid nephropathy and protective effects of Cozaar[J]. Ren Fail, 2012, 34(1): 60.
[7]
白永恒,洪炜龙,刘彪彭,等. Sonic hedgehog 肾小管上皮细信号参与马兜铃酸损伤胞的体外实验研究 [J]. 中国肾脏病杂志,2013, 29(4):288.
Ding Y J, Chen Y H. Developmental nephrotoxicity of aristolochic acid in a zebrafish model[J]. Toxicol Applied Pharmacol,2012, 261(1): 59.
[10]
Hwang Y H, Kim T, Cho W K,et al. In vitro and in vivo genotoxicity assessment of aristolochia manshuriensis Kom[J]. Evid Based Complement Altern Med, 2012,doi: 2012/412736.
[11]
Nitzsche D, Melzig M F, Arlt V M. Evaluation of the cytotoxicity and genotoxicity of aristolochic acid I ——a component of Aristolochiaceae plant extracts used in homeopathy[J]. Environ Toxicol Pharmacol, 2013, 35(2): 325.
[12]
Sidorenko V S, Yeo J E, Bonala R R,et al. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts[J]. Nucleic Acids Res, 2012, 40(6): 2494.
Xing G, Qi X, Chen M,et al. Comparison of the mutagenicity of aristolochic acid I and aristolochic acid Ⅱ in the gpt delta transgenic mouse kidney[J]. Mutat Res, 2012, 743(1/2): 52.
[15]
National Toxicology P. Final report on carcinogens background document for aristolochic acids[J]. Rep Carcinog Backgr Doc,2008,21:3126.
Liu G M, Fang Q, Ma H S,et al. Distinguishing characteristics of urothelial carcinoma in kidney transplant recipients between China and Western countries[J]. Transplant Proceedings, 2013, 45(6): 2197.
[18]
Hoang M L, Chen C H, Sidorenko V S,et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing[J]. Sci Translat Med, 2013, 5(197): 102.
[19]
Schmeiser H H, Kucab J E, Arlt V M,et al. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania[J]. Environ Mol Mutag, 2012, 53(8): 636.
[20]
谌贻璞,陈文.马兜铃酸肾病的研究进展 [J].肾脏病与透析肾移植杂志,2002,11(1):63.
[21]
Yang L, Su T, Li X M,et al. Aristolochic acid nephropathy: variation in presentation and prognosis[J]. Euro Ren Assoc, 2012, 27(1): 292.
[22]
Tang Z, Chen D, Zhang Y,et al. Acute kidney injury induced by aristolochic acid in patients with primary glomerular nephritis[J]. Ren Fail, 2013,14:1265.
[23]
Poon S L, Pang S T, McPherson J R,et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool[J]. Sci Translat Med, 2013, 5(197): 101.
[24]
Fuchs T C, Mally A, Wool A,et al. An exploratory evaluation of the utility of transcriptional and urinary kidney injury biomarkers for the prediction of aristolochic acid-induced renal injury in male rats[J]. Veterin Pathol, 2013,8:1042.
[25]
Huang T C, Chen S M, Li Y C,et al. Urinary d-lactate levels reflect renal function in aristolochic acid-induced nephropathy in mice[J]. Biomed Chromatogr,2013, 27(9): 1100.
[26]
Stiborova M, Martinek V, Frei E,et al. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer[J]. Curr Drug Metab, 2013, 14(6): 695.
[27]
Feng C, Xie X, Wu M,et al. Tanshinone I protects mice from aristolochic acid I-induced kidney injury by induction of CYP1A[J]. Environ Toxicol Pharmacol, 2013, 36(3): 850.
[28]
Stiborova M, Levova K, Barta F,et al. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2[J]. Toxicol Sci, 2012, 125(2): 345.
[29]
Baudoux T E, Pozdzik A A, Arlt V M,et al. Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy[J]. Kidney Int, 2012, 82(10): 1105.
[30]
Rui H L, Wang Y Y, Cheng H,et al. JNK-dependent AP-1 activation is required for aristolochic acid-induced TGF-beta1 synthesis in human renal proximal epithelial cells[J]. Amer J Physiol Renal Physiol, 2012, 302(12): 1569.
[31]
Novitskaya T, McDermott L, Zhang K X,et al. A PTBA class small molecule enhances recovery and reduces post injury fibrosis after aristolochic acid-induced kidney injury[J]. Ame J Physiol Ren Physiol, 2013,10:2145.
[32]
Chen G, Chen H, Wang C,et al. Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts[J]. PLoS ONE, 2012, 7(3): e33626.
[33]
刘美凤.综合疗法治疗急性马兜铃中毒16例[J].中国中医急症,2010,19(3):516.
[34]
Michl J, Jennings H M, Kite G C,et al. Is aristolochic acid nephropathy a widespread problem in developing countries A case study of Aristolochia indica L. in Bangladesh using an ethnobotanical-phytochemical approach[J]. J Ethnopharmacol, 2013, 149(1): 235.
[35]
Heinrich M, Chan J, Wanke S,et al. Local uses of Aristolochia species and content of nephrotoxic aristolochic acid 1 and 2——a global assessment based on bibliographic sources[J]. J Ethnopharmacol, 2009, 125(1): 108.
[36]
Pavlovic N M, Maksimovic V, Maksimovic J D,et al. Possible health impacts of naturally occurring uptake of aristolochic acids by maize and cucumber roots: links to the etiology of endemic (Balkan) nephropathy[J]. Environ Geochem Health, 2013, 35(2): 215.
[37]
Yang H Y, Wang J D, Lo T C, et al. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists[J]. J Urol, 2013, 189(1): 48.
Karanovic S, Lela I V, Jelakovic B,et al. Variation in presentation and presence of DNA adducts and p53 mutations in patients with endemic nephropathy——an environmental form of the aristolochic acid nephropathy[J]. Kidney Blood Press Res, 2013, 37(1): 1.
[41]
Wu F, Wang T. Risk assessment of upper tract urothelial carcinoma related to aristolochic acid[J]. Cancer Epidemiol Biomarkers Prev, 2013, 22(5): 812.
Chen C H,Dickman K G,Huang C Y,et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes[J]. Int J Cancer,2013,133(1): 14.
